CoChat
Cited by 244

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Assessment of nivolumab benefit–risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors

Open access
Zhao, X., Suryawanshi, S., Hruska, M., Feng, Y., Wang, X., Shen, J., Vezina, H.E., McHenry, M.B., Waxman, I.M., Achanta, A., Bello, A., Roy, A., Agrawal, S. · 2017 · Annals of Oncology

Abstract

BACKGROUND: Nivolumab 3 mg/kg every 2 weeks (Q2W) has shown benefit versus the standard of care in melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC). However, flat dosing is expected to shorten preparation time and improve ease of administration. With knowledge of nivolumab safety, efficacy, and pharmacokinetics across a wide dose range in body weight (BW) dosing, assessment of the benefit-risk profile of a 240-mg flat dose relative to the approved 3-mg/kg dose was approached by quantitative clinical pharmacology. PATIENTS AND METHODS: A flat dose of 240 mg was selected based on its equivalence to the 3-mg/kg dose at the median BW of ∼80 kg in patients in the nivolumab program. The benefit-risk profile of nivolumab 240 mg was evaluated by comparing exposures at 3 mg/kg Q2W and 240 mg Q2W across BW and tumor types; clinical safety at 3 mg/kg Q2W by BW and exposure quartiles in melanoma, NSCLC, and RCC; and safety and efficacy at 240 mg Q2W relative to 3 mg/kg Q2W in melanoma, NSCLC, and RCC. RESULTS: The median nivolumab exposure and its distribution at 240 mg Q2W were similar to 3 mg/kg Q2W in the simulated population. Safety analyses did not demonstrate a clinically meaningful relationship between BW or nivolumab exposure quartiles and frequency or severity of adverse events. The predicted safety and efficacy were similar across nivolumab exposure ranges achieved with 3 mg/kg Q2W or 240 mg Q2W flat dose. CONCLUSION: Based on population pharmacokinetic modeling, established flat exposure-response relationships for efficacy and safety, and clinical safety, the benefit-risk profile of nivolumab 240 mg Q2W was comparable to 3 mg/kg Q2W. The quantitative clinical pharmacology approach provided evidence for regulatory decision-making on dose modification, obviating the need for an independent clinical study.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/annonc/mdx235

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • The blockade of immune checkpoints in cancer immunotherapy

    Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838

  • Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

    Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · cited 2×

    “Despite the higher predicted exposures in patients with lower BW receiving the flat dosing regimen, the median and 90% prediction intervals of nivolumab summary exposures across the BW range was maintained well below the corresponding median and 95th percentile exposures observed with nivolumab 10 mg/kg Q2W, the clini…”
    BackgroundSelf-citation
  • Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

    Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335 · cited 1×

    “Clinical trials with nivolumab 3 mg/kg every 2 weeks (Q2W) showed an overall survival (OS) benefit over standard of care in several cancers, including advanced melanoma [2], squamous [3], and nonsquamous [4] non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC) [5], and squamous cell carcinoma of the head and…”
    Background
  • Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

    Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447 · cited 1×

    “Clinical trials with nivolumab 3 mg/kg every 2 weeks (Q2W) showed an overall survival (OS) benefit over standard of care in several cancers, including advanced melanoma [2], squamous [3], and nonsquamous [4] non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC) [5], and squamous cell carcinoma of the head and…”
    Background
  • Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

    Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807

    Self-citation
  • Nivolumab in Previously Untreated Melanoma without BRAF Mutation

    Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519 · cited 1×

    “Clinical trials with nivolumab 3 mg/kg every 2 weeks (Q2W) showed an overall survival (OS) benefit over standard of care in several cancers, including advanced melanoma [2], squamous [3], and nonsquamous [4] non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC) [5], and squamous cell carcinoma of the head and…”
    BackgroundSelf-citation
  • Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

    Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602252 · Cited by 5,101

Cited by

See all 244

Metadata

Authors
Zhao, X., Suryawanshi, S., Hruska, M., Feng, Y., Wang, X., Shen, J., Vezina, H. E., McHenry, M. B., Waxman, I. M., Achanta, A., Bello, A., Roy, A., & Agrawal, S.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2017-08
Volume
28
Issue
8
Pages
2002-2008
ISSN
0923-7534 (ISSN-L)
OpenAlex
W2615652585
Cited by
244
References
7
FWCI
9.26
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.